Cytomegalovirus (CMV) disease causes significant morbidity and mortality in patients receiving solid organ or hematopoietic stem cell transplants (SOT and HSCT, respectively). If left uncontrolled, CMV can result in high viral loads and end organ damage (EOD) in immunocompromised people. Active CMV infections are associated with additional potentially life-threatening complications, such as venous thrombosis, pneumonitis, and colitis.
It is imperative that clinicians are aware of recently approved treatment options for CMV disease. Additionally, clinicians must also be able to individualize CMV treatment to each patient as well as differentiate the benefits of monotherapy versus combination therapy.
In this CMEO Snack, join expert faculty as they discuss best strategies to identify risk factors of CMV infection, recognize the impact of CMV on treatment outcomes, and ultimately develop balanced treatment plans for patients with CMV disease.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in transplants, infectious disease, internal medicine, and/or primary care
it is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chemaly reports the following financial relationships: Advisory Board: ADMA Biologics, Inc.; Janssen Pharmaceuticals, Inc.; Karius, Inc.; Partner Therapeutics, Inc.; Pulmotect, Inc.; and Shionogi Inc. Consultant: Adagio Therapeutics, Inc.; Ansun Biopharma; Genentech, Inc.; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; Qiagen; and Takeda Pharmaceuticals U.S.A., Inc./Shire Pharmaceuticals. Grants: National Institutes of Health (NIH)/National Cancer Institute (NCI) (RO1). Research Support: AiCuris Anti-infective Cures AG; Ansun Biopharma; Chimerix; Eurofins Viracor; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Karius, Inc.; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc./Shire Pharmaceuticals
Dr. Papanicolaou reports the following financial relationships: Advisory Board: Cidara Therapeutics, Inc.; CSL Behring; Merck & Co., Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Consultant: AlloVir; Amplyx Pharmaceuticals, Inc.; Octapharma USA, Inc.; and Symbio Grants: Merck & Co., Inc. Research Support: Merck & Co., Inc. and Takeda Pharmaceuticals U.S.A., Inc.
Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
Janan Sarwar, PharmD (planning committee)
David Modrak, PhD (planning committee)
Evan Luberger (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sharon Tordoff (planning committee)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.
Call us at 877.CME.PROS (877.263.7767).